<DOC>
	<DOCNO>NCT00276081</DOCNO>
	<brief_summary>To compare efficacy safety gabapentin , estrogen placebo treatment hot flash climacteric symptom .</brief_summary>
	<brief_title>Gabapentin Versus Estrogen Treatment Hot Flashes</brief_title>
	<detailed_description>HRT associate increase risk thrombo-embolic event , breast cancer cardiovascular event . Safe , effective , well-tolerated alternative therapy hot flash need . Gabapentin gamma-aminobutyric acid ( GABA ) -analog report associated reduction frequency hot flash postmenopausal woman take gabapentin indication . However , know whether efficacy gabapentin treatment hot flash menopausal symptom comparable estrogen , gold standard . For study , 60 subject recruit randomize 3 arm 20 ( gabapentin , estrogen placebo ) .We perform analysis result 60 subject recruit , screen , enrol complete study . The investigator study continue blind study group randomization . To determine gabapentin approach efficacy estrogen treatment hot flash , postmenopausal woman age 35 60 7-20 moderate-severe postmenopausal hot flashes/day randomize double-blinded placebo control trial estrogen , gabapentin placebo . All patient must meet stringent inclusion exclusion criterion . Pre- post-study hot flash diary , depression climacteria scale collect . Patients require undergo physical examination blood work complete daily hot flash medication compliance record . Hot flash frequency composite score hot flash calculate three group base hot flash diary . Side effect , climacteric scale depression scale also use .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>1 . Menopausal woman age 3560 2 . Must experience 720 , moderatesevere hot flashes/day 50140 moderatesevere hot flashes/week great two month 3 . Must bilateral salpingooopherectomy &gt; 12 month amenorrhea &gt; 6 month # 4 ( ) 4 . Has FSH &gt; 30 mIU/ml 5 . Must sign informed consent 6 . Able function independent activity daily live capable reliable documentation 1 . Any contraindication estrogen progesterone replacement therapy 2 . History MI , stroke , and/or functional decline . 3 . Fails record data hot flash diary &gt; 3 day 2 week baseline period . 4 . Unable willing make require visit specify time course therapy . 5 . History malignancy undiagnosed vaginal bleeding . 6 . History chronic liver , gallbladder , chronic renal , cardiac endocrine disease</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Hot flash</keyword>
	<keyword>postmenopausal</keyword>
	<keyword>climacteric symptom</keyword>
	<keyword>hormone replacement therapy</keyword>
	<keyword>gabapentin</keyword>
</DOC>